CPT code 86592 represents a nontreponemal serologic screening test for syphilis—commonly performed as RPR, ART, or VDRL—to detect reagin antibodies in patient specimens. This screening code is nationally relevant because syphilis testing is a routine component of sexually transmitted infection (STI) screening, prenatal care, blood donor screening, and diagnostic evaluation for symptomatic patients, influencing public health surveillance and clinical workflows.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for nontreponemal testing, expected sites of service (clinical and hospital laboratories), and common billing considerations tied to laboratory workflows. The publication provides benchmarks for utilization and payment patterns, common modifier usage, and notes on coding relationships to other syphilis testing modalities.

The content also outlines policy updates that affect laboratory reimbursement and documentation expectations at the national level, and it clarifies distinctions between screening nontreponemal tests and confirmatory treponemal methods. Data not available in the input is noted where applicable; the focus remains on operational and coding clarity for payers, laboratory managers, and billing staff.